NasdaqGS:PCRXPharmaceuticals
Pacira BioSciences (PCRX) Advances PCRX 201 As Its Undervalued Narrative Faces A Fresh Test
Pacira BioSciences (PCRX) has advanced PCRX-201, its osteoarthritis gene therapy candidate, to a scalable U.S. commercial manufacturing process and has begun enrolling patients in Part B of the Phase 2 ASCEND study.
See our latest analysis for Pacira BioSciences.
The latest PCRX-201 update comes as Pacira BioSciences trades at US$26.92, with a 30 day share price return of 6.03% and a 90 day share price return of 13.63%. Over five years, the total shareholder return has declined 52.07%,...